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Background: MicroRNA-21 (miR-21) is an oncogenic microRNA that regulates the expression of multiple cancer-related
target genes. miR-21 has been associated with progression of some types of cancer. Metastasis-associated protein1
expression and loss of E-cadherin expression are correlated with cancer progression and metastasis in many cancer
types. In advanced colorectal cancer, the clinical significance of miR-21 expression remains unclear. We aimed to
investigate the impact of miR-21 expression in advanced colorectal cancer and its correlation with target proteins
associated with colorectal cancer progression.
Methods: From 2004 to 2007, 277 consecutive patients with T3-4a colorectal cancer treated with R0 surgical
resection were included. Patients with neoadjuvant therapy and distant metastasis at presentation were excluded.
The expression of miR-21 was investigated by in situ hybridization. Immunohistochemistry was used to detect
E-cadherin and metastasis-associated protein1 expression.
Results: High stromal expression of miR-21 was found in 76 of 277 (27.4%) colorectal cancer samples and was
correlated with low E-cadherin expression (P = 0.019) and high metastasis-associated protein1 expression (P = 0.004).
T3-4a colorectal cancer patients with high miR-21 expression had significantly shorter recurrence-free survival than
those with low miR-21 expression. When analyzing colon and rectal cancer separately, high expression of miR-21 was
an independent prognostic factor of unfavorable recurrence-free survival in T3-4a colon cancer patients (P = 0.038,
HR = 2.45; 95% CI = 1.05-5.72) but not in T3-4a rectal cancer patients. In a sub-classification analysis, high miR-21
expression was associated with shorter recurrence-free survival in the stage II cancer (P = 0.001) but not in the
stage III subgroup (P = 0.267).
Conclusions: Stromal miR-21 expression is related to the expression of E-cadherin and metastasis-associated
protein1 in colorectal cancer. Stage II colorectal cancer patients with high levels of miR-21 are at higher risk for
tumor recurrence and should be considered for more intensive treatment.
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Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in Korea [1]. The prognosis of CRC is
associated with tumor progression; five-year survival
rates range from 93% to 8% [2]. There are many pro-
posed serological and molecular markers as predictive
and prognostic indicators of CRC; however, they are not* Correspondence: ckjung@catholic.ac.kr
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mation due to a lack of reproducibility, validation and
standardization among studies [3,4]. Therefore, there is
a need to identify more reliable prognostic mediators of
tumor progression and metastasis in order to define the
behavior of CRC and improve postoperative treatment
strategies.
MicroRNAs are small noncoding RNA molecules, 18-25
nucleotides in length, which post-transcriptionally regu-
late gene expression by binding to the 3’ untranslated
regions of target messenger RNAs and play a centralhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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have been shown to influence all cellular processes [6]
and have a high degree of sequence conservation among
distantly related organism, indicating their likely partici-
pation in essential biological processes [7]. Of note, micro-
RNAs have been reported to have a marked influence on
carcinogenesis through the dysregulation of oncogenes
and tumor suppressor genes [8]. Cancer-related micro-
RNAs typically show altered expression levels in tumors
as compared to the level of expression in the correspond-
ing normal tissue.
MicroRNA-21 (miR-21) is an oncogenic microRNA that
regulates the expression of multiple cancer-related target
genes, such as PTEN and PDCD4, and has been reported
to be consistently up-regulated in various types of cancers,
including colon, breast, lung, and stomach cancers [9-16].
MiR-21 is known to contribute to the regulation of apop-
tosis, cell proliferation and migration [9,11,17]. Moreover,
miR-21 levels increase in the advanced stages of cancer,
suggesting a central role for miR-21 in invasion and
dissemination of cancer [12,14]. In CRC tissue sam-
ples, miR-21 expression is up-regulated during tumor
progression and is also known to be associated with
poor survival and response to chemotherapy [12,13,18].
However, the clinical significance of miR-21 expression in
advanced CRC remains unclear.
In situ hybridization (ISH) for microRNA has an ad-
vantage over quantitative microRNA expression analysis
platforms in that ISH allows for precise histological
localization of microRNAs in formalin-fixed paraffin-
embedded tissue blocks [19,20].
Loss of E-cadherin expression is associated with activa-
tion of epithelial-mesenchymal transition, invasion and
metastasis in various cancers [21]. Conversely, expression
of Metastasis-associated protein1 (MTA1) is correlated
with cancer progression and metastasis in numerous can-
cer types, including CRC [22,23]. Previous studies on the
association between MTA1 and E-cadherin have shown
that MTA1 regulates E-cadherin expression through AKT
activation in prostate cancer, and that low E-cadherin
expression promotes cancer metastasis [21,24]. However,
the exact role of these proteins in CRC remains unclear.
We investigated miR-21 expression using ISH in speci-
mens from T3-4a CRC patients treated by surgical resec-
tion. We also evaluated the relationship between expression
of miR-21, E-cadherin and MTA1 and their clinical signifi-




From January 2004 until June 2007, a total of 526 con-
secutive patients underwent surgical resection for CRC
at Seoul St. Mary’s Hospital. Of these, 277 patients withpathological T3 (invasion of the subserosa or pericolic/
perirectal adipose tissue) or T4a (serosal invasion) cancer
were selected for the study, based on the following inclu-
sion criteria: (i) no neoadjuvant chemotherapy or radiation
therapy, (ii) no evidence of direct invasion into adjacent
structures or organs, (iii) no postoperative death within
six weeks, and (iv) no distant metastasis at presentation.
The patients consisted of 181 males and 96 females (mean
age 63.0 years). Overall survival (OS) was defined as the
time interval between surgery and death from any cause
or the most recent follow-up date. Recurrence-free sur-
vival (RFS) was defined as the time from the date of sur-
gery to the date of first cancer recurrence or the most
recent disease-free follow-up. This study was approved
by the Institutional Review Board of Seoul, St. Mary’s
Hospital, The Catholic University of Korea. Written in-
formed consent was obtained from all patients.
Tissue microarray construction
We constructed tissue microarrays from formalin-fixed,
paraffin-embedded tissues as previously described [25,26].
Two 2-mm-diameter tissue cores were collected from
each representative tumor specimen and inserted in a re-
cipient paraffin block. The tissue microarray blocks were
serially cut into 4-μm-thick sections for immunohisto-
chemistry and 6-μm-thick sections for ISH.
Immunohistochemistry for E-cadherin and MTA1
Immunohistochemical staining was performed using
specific antibodies against E-cadherin (4A2C7, Zymed,
South San Francisco, CA), MTA1 (A-11, Santa Cruz
Biotechnology, Santa Cruz, CA) and the Polink-2 plus poly-
mer HRP detection system (Golden Bridge International,
Mukilteo, WA, USA) according to each manufacturer’s
protocol. The specificity of each antibody was confirmed
using both Western blotting and immunocytochemistry in
several cell lines with known protein expression status.
Negative controls were performed by the substitution of
the primary antibodies with normal mouse IgG at the
same concentration as the primary antibodies. Multi-
tissue blocks containing known-positive tumor tissues
were used as positive controls. Staining was examined
in triplicate by two gastrointestinal pathologists (CKJ
and SHL) who were blinded to the clinicopathological
data. Specimens with discordant interpretations were
reviewed until an agreement was reached. Immunohisto-
chemical staining results were only assessed by a semi-
quantitative score of staining intensity (0, no; 1, weak; 2,
moderate; 3, strong staining) because nearly all positively-
staining tumors showed a diffuse staining pattern for both
proteins. These scores were subsequently used to group
samples into two categories: low (0 or 1) and high staining
(2 or 3). Membrane staining of E-cadherin was evaluated
and scored as ‘2’ when tumor cells displayed staining
Table 1 Correlations of clinicopathological parameters
and expression of miR-21 in 277 patients with T3-4a
colorectal cancer
Parameter N miR-21 expression p-value
High Low
Age
<65 139 36 (25.9%) 103 (74.1%) 0.565
≥65 138 40 (29.0%) 98 (71.0%)
Gender
Male 181 51 (28.2%) 130 (71.8%) 0.705
Female 96 25 (26.0%) 71 (74.0%)
Primary site
Right colon 82 20 (24.4%) 62 (75.6%) 0.636
Left colon 91 28 (30.8%) 63 (69.2%)
Rectum 104 28 (26.9%) 76 (73.1%)
Histologic type
Non-mucinous 262 73 (27.9%) 189 (72.1%) 0.767
Mucinous 15 3 (20.0%) 12 (80.0%)
Differentiation
Well or moderately 260 74 (28.5%) 186 (71.5%) 0.168
Poorly 17 2 (11.8%) 15 (88.2%)
Depth of invasion
pT3 228 65 (28.5%) 163 (71.5%) 0.388
pT4a 49 11 (22.4%) 38 (77.6%)
Lymph node metastasis
Absent 138 39 (28.3%) 99 (71.7%) 0.759
Present 139 37 (26.6%) 102 (73.7%)
AJCC stage 0.118
IIA 122 34 (27.9%) 88 (72.1%)
IIB 16 5 (31.2%) 11 (68.8%)
IIIB 82 28 (34.1%) 54 (65.9%)
IIIC 57 9 (15.8%) 48 (84.2%)
Perineural invasion
Absent 219 58 (26.5%) 161 (73.5%) 0.490
Present 58 18 (31.0%) 40 (69.0%)
Lymphatic invasion
Absent 120 33 (27.5%) 87 (72.5%) 0.984
Present 157 43 (27.4%) 114 (72.6%)
Vascular invasion
Absent 255 72 (28.2%) 183 (71.8%) 0.311
Present 22 4 (18.2%) 18 (81.8%)
CEA (ng/dL)a
<5 163 46 (28.2%) 117 (71.8%) 0.542
≥5 78 25 (32.1%) 53 (67.9%)
Table 1 Correlations of clinicopathological parameters
and expression of miR-21 in 277 patients with T3-4a
colorectal cancer (Continued)
Adjuvant therapy
No 16 1 (6.2%) 15 (93.8%) 0.079
Yes 261 75 (28.7%) 186 (71.3%)
E-cadherin
Low 109 40 (36.7%) 69 (63.3%) 0.019
High 161 37 (23.0%) 124 (77.0%)
MTA1
Low 168 37 (22.0%) 131 (78.0%) 0.004
High 102 39 (38.2%) 63 (61.8%)
aPreoperative serum level of carcinoembryonic antigen (CEA) was measured in
241 colorectal cancer patients. AJCC, American Joint Committee on Cancer.
Immunohistochemistry for E-cadherin and MTA1 was available in 270 cases.
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MTA1 expression was evaluated as nuclear staining.
In situ hybridization for miR-21
ISH was performed using the miRCURY locked nucleic
acid (LNA) microRNA Detection FFPE microRNA ISH
Optimization Kit 2 (Exiqon, Vedbaek, Denmark) in a
StatSpin ThermoBrite Slide Hybridizer (Fisher Scientific,
Westwood, MA) as previously described [19]. We used a
double-digoxigenin-labeled LNA miR-21 probe (Exiqon,
sequence: 5′-TCAACATCAGT-CTGATAAGCTA-3′), a
positive control LNA U6 snRNA probe (Exiqon, sequence:
5′- CACGAATTTGCGTGTCATCCTT-3′) and a negative
control LNA scrambled microRNA probe (Exiqon, se-
quence: 5′- GTGTAACACGTCTATACGCCCA-3′). Tis-
sue sections were counterstained with nuclear fast red.
Semiquantitative assessment of the ISH staining results
was performed by two pathologists (CKJ and SHL) who
were unaware of the clinicopathological and immunohis-
tochemical data. In all cases where disagreements oc-
curred, a consensus was reached by the investigators. The
intensity of the staining was scored as negative (0), weak
(1), moderate (2), or strong (3), as previously described
[27,28], and samples were subsequently grouped into two
categories: low (0 or 1) and high (2 or 3) expression.
Statistical analysis
The relationships between the expression of miR-21,
E-cadherin and MTA1 and the clinicopathological param-
eters were analyzed using the Chi-square test. Cumulative
incidence curves for OS and RFS were plotted using the
Kaplan–Meier method. The long-rank test was used to
detect differences among groups. Multivariate analysis
for OS and RFS was conducted using the Cox proportional
hazard regression model. All statistical analyses were per-
formed using SPSS, version 16 (SPSS Inc., Chicago, IL). A
p value <0.05 was considered significant.
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and patient survival
Two authors (CKJ and SHL) performed literature searches
using PubMed, Embase databases and Google up to
November 2014, and independently selected eligible
articles. Inclusion criteria include 1) being related to
the association between miR-21 expression and CRC
prognosis, 2) original articles, and 3) sufficient RFS or
OS data including hazard ratio (HR) with a 95% confidence
interval (CI). We performed a meta-analysis of HR of the
effect of miR-21expression on RFS or OS in colon or rectal
cancer patients. Heterogeneity among studies was assessed
using Cochran Q test and I2 values. A P < 0.10 or I2 > 50%
was considered significant heterogeneity. If statistical het-
erogeneity was observed, the random effect model was used
for meta-analysis. Otherwise, we used a fixed-effect model
for the meta-analysis. Meta-analyses were performed using
Comprehensive Meta Analysis Version 2.0 (Biostat Inc.,
Englewood, NJ).
Results
Demographic and clinicopathological variables of the
study participants are listed in Table 1.
miR-21 expression by in situ hybridization
miR-21 expression was found to be predominantly local-
ized to the stroma surrounding the tumor cells (Figure 1).Figure 1 In situ hybridization for miR-21 and immunohistochemistry fo
from the colorectal cancer tissue microarray shows diffuse strong miR-21 exp
that miR-21 signals are strong in the stromal cells of colorectal cancer but not
membranous expression of E-cadherin. Magnification x400. (D) Tumor cells shHigh levels of miR-21 were found in 76 of 277 (27.4%)
CRC specimens. There was no significant correlation be-
tween high miR-21 expression and the clinicopathological
features of the patients (Table 1).
Correlation between miR-21 and MTA1/E-cadherin
expression
The expression patterns of E-cadherin and MTA1 in
stained tumor cells were membranous and nuclear, re-
spectively (Figure 1). Low expression of E-cadherin
was found in 109 of 277 (39.4%) CRCs, and high
MTA1 expression was seen in 102 (36.8%) tumors.
High miR-21 expression was significantly correlated
with low E-cadherin expression (P = 0.019) and high
MTA1 expression (P = 0.004) (Table 1). E-cadherin ex-
pression was negatively correlated with MTA1 expression
(P = 0.005).
Recurrence-free survival and overall survival
In all 277 CRC patients, variables significantly associ-
ated with RFS included miR-21 expression (P = 0.010,
Figure 2A), histological differentiation (P = 0.031), pT
stage (P = 0.0005), lymph node metastasis (P = 0.00001),
and serum CEA level (P =0.006) (Table 2). In a multivari-
ate analysis, high levels of miR-21 (P = 0.007, HR = 2.24;
95% CI = 1.25-4.02), pT stage, lymph node metastasis, and
serum CEA level were independent prognostic factors forr E-cadherin and MTA1. (A) A representative 2 mm tumor tissue core
ression in the stroma. (B) High-magnification image of insert in (A) shows
in the tumor cells. Magnification x400. (C) Tumor cells show strong
ow strong nuclear expression of MTA1. Magnification x400.
Figure 2 Association between miR-21 expression and recurrence-free survival in patients with T3-4a colorectal cancer. Kaplan-Meier
survival curves for recurrence-free survival in all (A), stage II (B) and stage III (C) cancer patients according to miR-21 expression status. (A) High
miR-21 expression is associated with recurrence-free survival in colon cancer patients but not in rectal cancer patients. (B) For the 138 patients
with stage II cancer, the association between high miR-21 expression and recurrence-free survival is statistically significant only in colon cancer
patients. (C) Among 277 stage III cancer patients, high miR-21 expression is not associated with poor recurrence-free survival.
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not associated with the expression levels of miR-21,
E-cadherin or MTA1.
To further understand the association of prognostic
factors and RFS according to the primary cancer site, we
analyzed their HRs for RFS in colon and rectal cancer
separately (Tables 3 and 4). High expression of miR-21was associated with shorter RFS in patients with T3-4a
colon cancer (n = 173, P = 0.005, Figure 2A), but not in
patients with T3-4a rectal cancer (n = 104, P = 0.474,
Figure 2A).
The T3-4a CRC patients were divided into subgroups
according to American Joint Committee on Cancer stage.
In the stage II (T3-4aN0M0) subgroup, we found that
Table 2 Univariate analysis for overall recurrence-free survival among patients with T3-4a colorectal cancer
Colorectal cancer (n = 277) Rectal cancer (n = 104) Colon cancer (n = 173)
Variables HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
miR-21 expression (low vs. high) 2.02 (1.18-3.45) 0.010 1.32 (0.62-2.85) 0.474 3.09 (1.41-6.76) 0.005
Age (<65 years vs. ≥65 years) 0.97 (0.57-1.66) 0.920 0.45 (0.20-1.02) 0.055 2.12 (0.95-4.77) 0.068
Tumor type (non-mucinous vs. mucinous) 1.18 (0.37-3.78) 0.783 3.03 (0.70-13.05) 0.138 0.67 (0.09-4.94) 0.693
Differentiation (well or moderately vs. poorly) 2.56 (1.09-6.00) 0.031 4.57 (1.33-15.67) 0.016 2.06 (0.60-7.00) 0.249
pT (T3 vs. T4a) 2.68 (1.51-4.76) 0.0005 3.97 (1.73-9.12) 0.001 2.30 (1.00-5.30) 0.044
Lymph node metastasis (absent vs. present) 3.69 (1.98-6.87) 0.00001 6.65 (2.30-19.22) 0.0004 2.24 (1.00-5.02) 0.045
CEA (<5 ng/dL vs. ≥5 ng/dL) 2.24 (1.26-3.99) 0.006 2.26 (1.02-5.05) 0.046 2.23 (0.97-5.15) 0.060
Adjuvant therapy (no vs. yes) 4.19 (0.58-30.35) 0.156 NA NA 3.23 (0.44-23.98) 0.252
HR, hazard ratio; CI, confidence interval; NA, not available.
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cantly shorter RFS time than those with low miR-21 level
regardless of the primary site (colon cancer, P = 0.007; rec-
tal cancer, P = 0.030, Figure 2B). However, in the stage III
(T3-4aN1M0) subgroup, there was no significant differ-
ence in RFS between patients with high or low levels of
miR-21 expression (colon cancer, P = 0.053; rectal cancer,
P = 0.588, Figure 2C).
Meta-analysis
A total of 10 studies were included for the meta-analysis
and their characteristics are summarized in Table 4
[13,18-20,29-34]. High heterogeneity was found in the
analysis. For all CRC patients, high miR-21 expression
was significantly associated with poor RFS (HR = 1.327,
95% CI = 1.053-1.673, Figure 3) and poor OS (HR = 1.272,
95% CI = 1.065-1.519, Figure 4). In subgroup analysis, the
high miR-21 expression was significantly correlated with
poor RFS and OS in colon cancer patients (HR = 1.423,
95% CI = 1.280-1.582; HR = 1.357, 95% CI = 1.102-1.672,
respectively), but not in rectal cancer or CRC patients.Table 3 Multivariate analysis of prognostic factors predicting
location
Colorectal cancer (n = 27
Variables HR (95% CI) p-va
miR-21 expression (low vs. high) 2.24 (1.25-4.02) 0.00
Age (<65 years vs. ≥65 years) 1.03 (0.56-1.89) 0.92
Tumor type (non-mucinous vs. mucinous) 0.61 (0.13-2.97) 0.53
Differentiation (well or moderately vs. poorly) 2.18 (0.83-5.71) 0.11
pT (T3 vs. T4a) 1.97 (1.01-3.83) 0.04
Lymph node metastasis (absent vs. present) 4.55 (2.23-9.29) 0.00
CEA (<5 ng/dL vs. ≥5 ng/dL) 2.63 (1.46-4.74) 0.00
Adjuvant therapy (no vs. yes) 2.48 (0.32-19.32) 0.38
HR, hazard ratio; CI, confidence interval; NA, not available. Multivariate analysis is ad
mucinous), differentiation (well or moderately vs. poorly), pT (T3 vs. T4a), lymph no
therapy (no vs. yes).Discussion
In the present study, we detected high miR-21 expression
in 27.1% (81 of 299) of T3-4a CRCs, and this was associ-
ated with low E-cadherin expression and high MTA1
expression. The multivariate analysis revealed that high
miR-21 expression was an independent predictor of tumor
recurrence in patients with T3-4a CRC.
We observed that miR-21 overexpression occurred in
the stroma rather than in the actual tumor cells. Previous
studies have reported that miR-21 predominantly localizes
to fibroblast-like cells within the tumor-associated stroma
of CRC, breast cancer and esophageal cancer [19,35,36].
Using high sensitivity TaqMan quantitative RT-PCR assays
in microdissected tissue, Bullock et al. found that miR-21
expression was undetectable in CRC tumor cells but was
present in the tumor-associated stroma [35]. Up-regulated
miR-21 expression in CRC-associated stroma was associ-
ated with transforming growth factor TGF-β-dependent
fibroblast-to-myofibroblast transformation and with de-
creased expression of reversion-inducing cysteine-rich
protein with Kazal motifs [35]. The authors proposedoverall recurrence-free survival according to cancer
7) Rectal cancer (n = 104) Colon cancer (n = 173)
lue HR (95% CI) p-value HR (95% CI) p-value
7 1.65 (0.65-4.16) 0.295 2.45 (1.05-5.72) 0.038
4 0.27 (0.10-0.70) 0.007 2.48 (1.00-6.12) 0.049
9 0.62 (0.03-11.50) 0.751 1.03 (0.13-8.48) 0.976
4 2.60 (0.55-12.21) 0.225 1.56 (0.41-5.94) 0.513
6 2.26 (0.75-6.79) 0.145 2.27 (0.86-5.97) 0.098
003 11.75 (3.33-41.48) 0.0001 3.02 (1.22-7.47) 0.017
1 3.32 (1.39-7.51) 0.006 2.65 (1.13-6.21) 0.025
6 NA NA 2.15 (0.26-18.08) 0.431
justed for age (<65 years vs. ≥65 years), tumor type (non-mucinous vs.
de metastasis (absent vs. present), CEA (<5 ng/dL vs. ≥5 ng/dL) and adjuvant













methodHR 95% CI HR 95% CI
Schetter [13] 2008 USA aCC 71 I-IV NA NA 2.7 1.3-5.5 Third tertile Multivariate RT-PCR
China aCC 103 I-IV NA NA 2.4 1.4-4.1 Dichotomize Multivariate Microarray
Shibuya [18] 2010 Japan CRC 156 I-IV 0.396 0.186-0.897 0.513 0.280-0.956 Mean Multivariate RT-PCR
Nielsen [19] 2011 Denmark CC 129 II 1.28 1.06-1.55 1.17 1.02-1.34 Dichotomize Multivariate ISH
RC 67 II 0.85 0.73–1.01 0.97 0.83-1.13 Dichotomize Multivariate ISH
Kjaer-Frifeldt [20] 2012 Denmark CC 764 II 1.41 1.19-1.67 1.05 0.94-1.18 Mean log Multivariate ISH
Zhang [29] 2013 China CC 138 II 1.98 0.95-4.15 NA NA Dichotomize Univariate RT-PCR
CC 137 II 1.88 0.95-3.75 NA NA Dichotomize Univariate RT-PCR
CC 255 II 1.79 1.22-2.62 NA NA Dichotomize Univariate RT-PCR
Bovell [30] 2013 USA CRC 55 IV NA NA 3.25 1.37-7.72 Mean Multivariate RT-PCR
Toiyama [31] 2013 Japan CRC 166 I-IV NA NA 0.59 0.21-1.63 3.7 Multivariate RT-PCR
Chen [32] 2013 Taiwan CRC 195 I-IV NA NA 1.655 0.992-2.762 Mean Univariate RT-PCR
Hansen [33] 2014 Denmark CC 554 II 1.348 1.032-1.760 1.075 0.889-1.301 Dichotomize Multivariate RT-PCR
Oue [34] 2014 Japan CC 156 I-IV NA NA 1.80 0.91-3.58 Third tertile Multivariate RT-PCR
CC 87 II-III NA NA 3.13 1.20-8.17 Third tertile Multivariate RT-PCR
Germany CC 145 II NA NA 2.65 1.06-6.66 Third tertile Multivariate RT-PCR
Present study Korea CC 173 II-III 3.09 1.41-6.76 0.425 0.142-1.271 Dichotomize Multivariate ISH
RC 104 II-III 1.32 0.62-2.85 2.046 0.557-7.513 Dichotomize Multivariate ISH
aOnly including patients with typical adenocarcinoma. AJCC, American Joint Committee on Cancer; CI, confidence interval; HR, hazard ratio; NA, not available; RT-PCR, reverse-transcription PCR; ISH, in situ hybridization;












Figure 3 Forest plot of meta-analysis for the association of high miR-21 expression and recurrence-free survival in colorectal cancer
patients. There is a statistically significant association between high miR-21 expression and poor recurrence-free survival in colon cancer patients.
The observed association is not statistically significant in rectal cancer. CI, confidence interval; CC, colon cancer; RC, rectal cancer; CRC, colorectal
cancer; RFS, recurrence-free survival.
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gression, and that miR-21 promoted chemo-resistance
and tumor invasion by increasing matrix metallopro-
teinase 2 activity [35]. These results suggest that miR-21
may regulate tumor progression through modulation of
the tumor microenvironment.
Recent studies have shown that high stromal miR-21
expression, as measured by ISH, is correlated with shorter
RFS in stage II colon cancer [19,20]. In the analysis of OS
in stage II colon cancer patients, Nielsen et al. [19] re-
ported on the prognostic significance of miR-21; while
Kjaer-Frifeldt et al. [20] were unable to show any signifi-
cant impact on OS. In the present study using ISH, we
found that stromal miR-21 expression was a prognostic
factor for RFS in stage II CRC patients but not in stage III
patients. Therefore, miR-21 overexpression may have an
important role in tumor progression and recurrence prior
to the development of lymph node or distant metastases.
We found no prognostic value for miR-21 in our analysis
of OS, which was calculated as the time from surgery to
time of death from any cause.
In the stratified meta-analysis by tumor site, we found
that high miR-21 expression was associated with shorterRFS and worse OS in colon cancer, but not in rectal can-
cer or CRC. The RFS results are consistent with findings
of present study.
It has been reported that MTA1 regulates E-cadherin
expression via AKT activation in prostate cancer, and
that miR-21 is required for regulation of phosphory-
lated AKT expression in glioblastoma multiforme
[24,37]. Xiong et al. suggested that miR-21 influences
tumor biology through the PTEN/PI-3 K/Akt pathway
in CRC [38]. In our immunohistochemical analysis of
E-cadherin and MTA1expression, high MTA1 level
was associated with low E-cadherin expression. The
expression profiles of these proteins were also signifi-
cantly correlated with miR-21 expression patterns.
Taken together, these results led us to hypothesize that
MTA1 may negatively regulate E-cadherin expression
via high miR-21 expression in CRC. However, further
studies will be needed to determine whether there is a dir-
ect role for miR-21 in regulation of MTA1 and E-cadherin
expression.
Our study has some limitations including the retro-
spective, single-institution design and the lack of valid-
ation of these results in an independent CRC patient
Figure 4 Forest plot of meta-analysis for the association of high miR-21 expression and overall survival in colorectal cancer patients.
High miR-21 expression is associated with poor overall survival in colon cancer patients but not in rectal cancer. CI, confidence interval; CC, colon
cancer; RC, rectal cancer; CRC, colorectal cancer; OS, overall survival.
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needed to evaluate the prognostic significance of miR-
21 expression.
Conclusion
miR-21 is overexpressed in the stroma of CRC speci-
mens and has strong associations with the expression
of E-cadherin and MTA1. A high level of miR-21 is an
independent risk factor predictive of early tumor re-
currence in T3-4a colon cancer and stage II CRC.
Thus, CRC patients with miR-21 overexpression are at
higher risk for tumor recurrence and may benefit from
more intensive treatment.
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